Adc Therapeutics Sa Stock Debt To Equity

ADCT Stock

USD 2.03 0.04 2.01%

ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	(0.77)	(0.73)

Debt To Equity is likely to gain to -0.73 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ADC Therapeutics SA Company Debt To Equity Analysis

ADC Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current ADC Therapeutics Debt To Equity

2.75 %

Most of ADC Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ADC Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Debt To Equity. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Short Term Debt	Long Term Debt	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab
Total Assets		-0.02	0.48	-0.81	-0.77	0.76	0.67	0.81	1.0	0.81	0.82	-0.29	-0.23	0.11	0.86	0.79	0.82	0.8	0.09	-0.41	0.58	0.43
Total Stockholder Equity	-0.02		-0.76	-0.49	0.6	-0.48	-0.33	-0.61	-0.03	-0.4	-0.35	0.78	0.82	0.93	0.13	-0.46	-0.41	0.09	0.38	0.88	-0.69	-0.77
Current Deferred Revenue	0.48	-0.76		0.0	-0.72	0.77	0.66	0.83	0.49	0.59	0.48	-0.71	-0.67	-0.64	0.35	0.64	0.53	0.25	-0.19	-0.82	0.8	0.76
Net Debt	-0.81	-0.49	0.0		0.34	-0.39	-0.19	-0.36	-0.82	-0.45	-0.48	-0.24	-0.12	-0.55	-0.8	-0.38	-0.46	-0.82	-0.34	-0.06	-0.06	0.08
Retained Earnings	-0.77	0.6	-0.72	0.34		-0.89	-0.67	-0.97	-0.78	-0.93	-0.91	0.73	0.68	0.52	-0.48	-0.91	-0.94	-0.53	0.21	0.85	-0.86	-0.82
Accounts Payable	0.76	-0.48	0.77	-0.39	-0.89		0.69	0.88	0.77	0.93	0.82	-0.7	-0.45	-0.45	0.44	0.87	0.82	0.49	0.05	-0.72	0.87	0.78
Net Receivables	0.67	-0.33	0.66	-0.19	-0.67	0.69		0.73	0.65	0.69	0.66	-0.58	-0.17	-0.21	0.49	0.72	0.66	0.2	-0.21	-0.46	0.8	0.68
Total Liab	0.81	-0.61	0.83	-0.36	-0.97	0.88	0.73		0.81	0.88	0.86	-0.68	-0.67	-0.46	0.6	0.89	0.89	0.58	-0.16	-0.84	0.86	0.79
Total Current Assets	1.0	-0.03	0.49	-0.82	-0.78	0.77	0.65	0.81		0.82	0.82	-0.27	-0.25	0.09	0.86	0.78	0.82	0.8	0.09	-0.43	0.59	0.45
Intangible Assets	0.81	-0.4	0.59	-0.45	-0.93	0.93	0.69	0.88	0.82		0.96	-0.68	-0.39	-0.36	0.47	0.96	0.96	0.58	0.05	-0.66	0.83	0.74
Common Stock	0.82	-0.35	0.48	-0.48	-0.91	0.82	0.66	0.86	0.82	0.96		-0.57	-0.38	-0.26	0.54	0.95	0.99	0.61	0.02	-0.63	0.79	0.71
Net Tangible Assets	-0.29	0.78	-0.71	-0.24	0.73	-0.7	-0.58	-0.68	-0.27	-0.68	-0.57		0.57	0.84	0.13	-0.7	-0.6	-0.05	0.28	0.71	-0.73	-0.71
Capital Surpluse	-0.23	0.82	-0.67	-0.12	0.68	-0.45	-0.17	-0.67	-0.25	-0.39	-0.38	0.57		0.75	-0.12	-0.38	-0.47	-0.15	0.54	0.91	-0.53	-0.64
Net Invested Capital	0.11	0.93	-0.64	-0.55	0.52	-0.45	-0.21	-0.46	0.09	-0.36	-0.26	0.84	0.75		0.39	-0.37	-0.32	0.22	0.4	0.78	-0.58	-0.68
Net Working Capital	0.86	0.13	0.35	-0.8	-0.48	0.44	0.49	0.6	0.86	0.47	0.54	0.13	-0.12	0.39		0.49	0.54	0.77	0.16	-0.23	0.34	0.21
Property Plant Equipment	0.79	-0.46	0.64	-0.38	-0.91	0.87	0.72	0.89	0.78	0.96	0.95	-0.7	-0.38	-0.37	0.49		0.95	0.61	0.11	-0.65	0.83	0.71
Capital Stock	0.82	-0.41	0.53	-0.46	-0.94	0.82	0.66	0.89	0.82	0.96	0.99	-0.6	-0.47	-0.32	0.54	0.95		0.6	-0.06	-0.69	0.79	0.73
Short Term Debt	0.8	0.09	0.25	-0.82	-0.53	0.49	0.2	0.58	0.8	0.58	0.61	-0.05	-0.15	0.22	0.77	0.61	0.6		0.46	-0.21	0.2	0.05
Long Term Debt	0.09	0.38	-0.19	-0.34	0.21	0.05	-0.21	-0.16	0.09	0.05	0.02	0.28	0.54	0.4	0.16	0.11	-0.06	0.46		0.39	-0.19	-0.34
Long Term Investments	-0.41	0.88	-0.82	-0.06	0.85	-0.72	-0.46	-0.84	-0.43	-0.66	-0.63	0.71	0.91	0.78	-0.23	-0.65	-0.69	-0.21	0.39		-0.83	-0.89
Short Long Term Debt	0.58	-0.69	0.8	-0.06	-0.86	0.87	0.8	0.86	0.59	0.83	0.79	-0.73	-0.53	-0.58	0.34	0.83	0.79	0.2	-0.19	-0.83		0.97
Deferred Long Term Liab	0.43	-0.77	0.76	0.08	-0.82	0.78	0.68	0.79	0.45	0.74	0.71	-0.71	-0.64	-0.68	0.21	0.71	0.73	0.05	-0.34	-0.89	0.97

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict ADC Therapeutics

Debt To Equity Over Time

ADC Total Stockholder Equity

Total Stockholder Equity

(140.84 Million)

At this time, ADC Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year.

According to the company disclosure, ADC Therapeutics SA has a Debt To Equity of 2.755%. This is 94.85% lower than that of the Communications Equipment sector and 85.77% lower than that of the Information Technology industry. The debt to equity for all United States stocks is 94.34% higher than that of the company.

ADC Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.

ADC Therapeutics is currently under evaluation in debt to equity category among its peers.

ADC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.0B	2.1B	1.6B	300.1M	135.6M	128.9M
Enterprise Value	1.9B	1.7B	1.2B	91.0M	(18.6M)	(17.6M)

ADC Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ADC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ADC Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

ADC Fundamentals

	Return On Equity	-7.06
	Return On Asset	-0.21
	Profit Margin	(3.00) %
	Operating Margin	(1.93) %
	Current Valuation	42.69 M
	Shares Outstanding	96.69 M
	Shares Owned By Insiders	21.02 %
	Shares Owned By Institutions	61.39 %
	Number Of Shares Shorted	3.17 M
	Price To Earning	19.80 X
	Price To Book	2.58 X
	Price To Sales	2.78 X
	Revenue	69.56 M
	Gross Profit	35.1 M
	EBITDA	(146.76 M)
	Net Income	(240.05 M)
	Cash And Equivalents	376.78 M
	Cash Per Share	4.90 X
	Total Debt	124.38 M
	Debt To Equity	2.75 %
	Current Ratio	5.76 X
	Book Value Per Share	(1.78) X
	Cash Flow From Operations	(118.69 M)
	Short Ratio	9.62 X
	Earnings Per Share	(2.44) X
	Price To Earnings To Growth	0.74 X
	Target Price	8.4
	Number Of Employees	273
	Beta	1.6
	Market Capitalization	196.28 M
	Total Asset	354.78 M
	Retained Earnings	(1.34 B)
	Working Capital	268.62 M
	Current Asset	1.11 B
	Current Liabilities	288.7 M
	Net Asset	354.78 M

About ADC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC